CYP19A1 and breast cancer: 2013; Cigler et al. 2010; Ferrari et al. 2002). Gallicchio et al. (2013) showed that aromatase inhibitors (AIs), the hormonal treatment for postmenopausal patients with oestrogen receptor‐positive breast cancer, frequently cause musculoskeletal pain (Gallicchio et al. 2013).